Drugs / CAR.70/IL15-transduced CB-NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05092451 | Nov 2022 → Aug 2026 overdue | Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, acute myeloid leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive +5 | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR.70/IL15-transduced CB-NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05092451 ↗ |
| Action | Deplete | “CAR27/IL-15 NK cells exerted potent in vitro and in vivo cytotoxicity against CD70+ multiple myeloma cells” PMID 41144785 ↗ Mar 2026 |
| Modality | Cell therapy | “immune cells called natural killer (NK) cells” NCT05092451 ↗ |
| Route | Intravenous | “Given by IV” NCT05092451 ↗ |
| Target | CD70 | “targeting CD70 in myeloma using NK cells engineered with a chimeric antigen receptor (CAR) incorporating the CD70 cognate receptor CD27 and IL-15 (CAR27/IL-15)” PMID 41144785 ↗ Mar 2026 |